Development and external validation of a prognosis model to predict outcomes after curative resection of early-stage intrahepatic cholangiocarcinoma

被引:2
作者
Wang, Jianping [1 ]
Huang, Manling [2 ,3 ]
Shen, Jingxian [4 ]
Li, Bin [5 ]
Wu, Yanqing [1 ]
Xie, Wenxuan [6 ]
Xiao, Han [7 ]
Tan, Li [3 ,5 ,6 ]
机构
[1] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol & Hepatol, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, Affiliated Hosp 1, Canc Ctr, Dept Oncol, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 1, Inst Precis Med, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Dept Med Imaging, State Key Lab Oncol Southern China, Canc Ctr, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 1, Clin Trials Unit, Guangzhou, Peoples R China
[6] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Hepatopancreato Biliary Surg, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Med Ultrason, Guangzhou, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
intrahepatic cholangiocarcinoma; resection; prognosis; risk; nomogram; CANCER; NOMOGRAM;
D O I
10.3389/fsurg.2023.1102871
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundEarly-stage intrahepatic cholangiocarcinoma (ESICC) with curative resection and lymph node-negative still has the risk of poor prognosis, and there lacks prognosis-assessing tools for these patients. The objective of this study was to develop a prognosis model to predict outcomes and identify risk stratification for ESICC after resection. MethodsTotally 263 patients with ESICC after hepatectomy from January 2012 to January 2022 were analyzed. Clinicopathological factors were selected using multivariable Cox regression analysis and a prognosis model was developed. The performance of the model was evaluated by concordance index (C-index), calibration plots, decision curves analysis (DCA), and net reclassification index (NRI). Kaplan-Meier curves were analyzed for risk stratification of overall survival (OS) and recurrence-free survival (RFS) based on the prognosis model. ResultsThe clinicopathological features that were independently associated with OS of ESICC included carbohydrate antigen19-9, carcinoembryonic antigen, tumor size, tumor differentiation, and T stage. The prognosis model based on these prognostic factors demonstrated excellent discriminatory performance in both derivation cohort (C-index, 0.71) and external validation cohort (C-index, 0.78), which outperformed the TNM staging system (C-index, 0.59) and individual prognostic factors (all C-index < 0.7). Calibration plots, DCA and NRI also showed superior predictive performance. According to the risk for survival, the model stratified patients into low risk (median OS, 66.6 months; median RFS, 24.3 months) and high risk (median OS, 24.0 months; median RFS, 6.4 months) (P < 0.001). ConclusionsOur prognosis model can robustly predict the outcomes of ESICC after curative resection and provide precise evaluation on prognosis risk, facilitating clinicians to develop individualized postoperative treatment options.
引用
收藏
页数:9
相关论文
共 31 条
[1]   The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging [J].
Amin, Mahul B. ;
Greene, Frederick L. ;
Edge, Stephen B. ;
Compton, Carolyn C. ;
Gershenwald, Jeffrey E. ;
Brookland, Robert K. ;
Meyer, Laura ;
Gress, Donna M. ;
Byrd, David R. ;
Winchester, David P. .
CA-A CANCER JOURNAL FOR CLINICIANS, 2017, 67 (02) :93-99
[2]  
[Anonymous], 2022, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines), B-cell Lymphomas, Version 5
[3]   Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma [J].
Bertuccio, Paola ;
Malvezzi, Matteo ;
Carioli, Greta ;
Hashim, Dana ;
Boffetta, Paolo ;
El-Serag, Hashem B. ;
La Vecchia, Carlo ;
Negri, Eva .
JOURNAL OF HEPATOLOGY, 2019, 71 (01) :104-114
[4]   Cholangiocarcinoma [J].
Brindley, Paul J. ;
Bachini, Melinda ;
Ilyas, Sumera I. ;
Khan, Shahid A. ;
Loukas, Alex ;
Sirica, Alphonse E. ;
Teh, Bin Tean ;
Wongkham, Sopit ;
Gores, Gregory J. .
NATURE REVIEWS DISEASE PRIMERS, 2021, 7 (01)
[5]   The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts [J].
Cao, Hop S. Tran ;
Zhang, Qianzi ;
Sada, Yvonne H. ;
Chai, Christy ;
Curley, Steven A. ;
Massarweh, Nader N. .
CANCER, 2018, 124 (01) :74-83
[6]   Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma [J].
Chen, Xing ;
Du, Jinpeng ;
Huang, Jiwei ;
Zeng, Yong ;
Yuan, Kefei .
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (03) :553-563
[7]   The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines [J].
Fong, Zhi Ven ;
Brownlee, Sarah A. ;
Qadan, Motaz ;
Tanabe, Kenneth K. .
ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (05) :2660-2674
[8]   Surgical Treatments of Hepatobiliary Cancers [J].
Gunasekaran, Ganesh ;
Bekki, Yuki ;
Lourdusamy, Vennis ;
Schwartz, Myron .
HEPATOLOGY, 2021, 73 :128-136
[9]   Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy? [J].
Gutierrez-Larranaga, Maria ;
Gonzalez-Lopez, Elena ;
Roa-Bautista, Adriel ;
Rodrigues, Pedro M. ;
Diaz-Gonzalez, Alvaro ;
Banales, Jesus M. ;
Lopez-Hoyos, Marcos ;
Santos-Laso, Alvaro ;
Crespo, Javier .
LIVER CANCER, 2021, 10 (06) :545-560
[10]   Adjuvant Therapy in the Treatment of Biliary Tract Cancer: A Systematic Review and Meta-Analysis [J].
Horgan, Anne M. ;
Amir, Eitan ;
Walter, Thomas ;
Knox, Jennifer J. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) :1934-1940